Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (LEAD)
This study is ongoing, but not recruiting participants.
Study NCT00701363   Information provided by Ipsen

First Received on June 18, 2008.   Last Updated on April 2, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acromegaly
More general conditions related to this trial
Bone Diseases
Bone Diseases, Endocrine
Brain Diseases
Central Nervous System Diseases
Endocrine System Diseases
Hyperpituitarism
Hypothalamic Diseases
Musculoskeletal Diseases
Nervous System Diseases
Pituitary Diseases
Interventions listed in this trial
Lanreotide Autogel 120 mg
Additional drug interventions recognized in this trial
Angiopeptin
Lanreotide
More general drug interventions related to this trial
Antineoplastic Agents
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Ipsen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services